VasoMedical, Inc.

VasoMedical, Inc. is a cardiovascular technology company with nearly 40 years of experience in cardiac diagnostics and therapy. The company specializes in two primary product areas: Enhanced External Counterpulsation (EECP®) therapy systems and next-generation cardiac monitoring platforms. Their Lumenair™ EECP® system is deployed in over 600 clinics across 40+ countries and is used for non-invasive therapy to improve coronary circulation, helping patients with angina and heart failure improve exercise tolerance and quality of life. In cardiac monitoring, VasoMedical offers the ARCS cloud-native platform, an FDA-cleared system for Holter, Extended Holter, Event, and Multi-Channel Telemetry (MCT) monitoring. ARCS features artifact-reduction algorithms, unified workflow management, and high-volume scanning capabilities designed to reduce manual rework and accelerate turnaround times. The company has analyzed over 1 billion heartbeats and delivered 12+ million hours of cardiac monitoring data. VasoMedical also provides the Advanced Cardiac Therapy (ACT) Program, a comprehensive utilization and operations model to help health systems optimize EECP program performance across cardiology, rehabilitation, and administrative workflows. The company serves hospitals, cardiology practices, rehabilitation clinics, and health systems ranging from private practices to major healthcare networks. Products are supported by FDA clearance for monitoring algorithms and established reimbursement pathways. VasoMedical combines hardware, software, and operational consulting to address both clinical and workflow challenges in cardiac care.